UBS analyst AJ Rice lowered the firm’s price target on UnitedHealth (UNH) to $410 from $430 and keeps a Buy rating on the shares. UBS is “feeling good” about UnitedHealth’s positioning for 2026, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth price target lowered to $385 from $415 at Oppenheimer
- UnitedHealth price target lowered to $375 from $409 at Morgan Stanley
- UnitedHealth selloff overdone, Cantor Fitzgerald sees buying opportunity
- UnitedHealth: Buy Rating Reaffirmed on Resilient Earnings, Margin Discipline, and Long-Term Growth Despite Medicare Policy Headwinds
- UnitedHealth price target lowered to $315 from $360 at BofA